Multidrug Resistance and the Lung Resistance-Related Protein in Human Colon Carcinoma SW-620 Cells

Kitazono, Masaki; Sumizawa, Tomoyuki; Takebayashi, Yuji; Chen, Zhe‐Sheng; Furukawa, Tatsuhiko; Nagayama, Shuichi; Tani, Akira; Takao, Sonshin; Aikou, Takashi; Akiyama, Shin-ichi

doi:10.1093/jnci/91.19.1647

Cited by 170 publications

(161 citation statements)

References 19 publications

Supporting

Mentioning

150

Contrasting

Unclassified

Order By: Relevance

“…19 This hypothesis has been corroborated by recent data regarding an MVP-dependent MDR phenotype induced by differentiation-inducing agents in colon cancer cells that was based on nuclear drug extrusion. 20 However, only a very few studies were able to localize considerable amounts of MVP at the nuclear membrane or in the nucleus. In most cell types, MVP was described to be localized in the cytoplasm or the perinuclear region.…”

Section: Discussionmentioning

confidence: 99%

Overexpression of the human major vault protein in astrocytic brain tumor cells

et al. 2001

View full text Add to dashboard Cite

Evidence has shown that the major human vault protein (MVP), which is identical to lung resistance-related protein (LRP), may be causally involved in a special type of multidrug resistance (MDR). The purpose of this study was to investigate the expression and cellular localization of MVP in cells derived from brain tumors and other tumors of neuroectodermal origin. Using both established cell lines (n ‫؍‬ 22) and primary explants (n ‫؍‬ 30), we show that a distinct overexpression of the MVP gene at the mRNA (RT-PCR) and protein (Western blot) levels is a characteristic feature of cells derived from astrocytic brain tumors. Primary cultures obtained from meningioma specimens also expressed high MVP levels, in contrast to neuroblastoma and medulloblastoma cells, which rarely contained detectable amounts of MVP. Normal human astrocytes cultured in vitro expressed MVP, although at low amounts compared with most malignant cell types. Basal MVP expression correlated with resistance against diverse antineoplastic drugs including anthracyclins, cisplatin and etoposide. By Western blot, MVP was also detected in all tumor samples taken from 7 glioma and 3 meningioma patients. Taken together, these data suggest overexpression of MVP as one explanation for the low efficacy of chemotherapeutic treatment of astrocytic brain tumors.

show abstract

Section: Discussionmentioning

confidence: 99%

Overexpression of the human major vault protein in astrocytic brain tumor cells

et al. 2001

View full text Add to dashboard Cite

show abstract

“…41 It was argued that these conflicting results might be due to patient population. 41 Akiyama et al showed that the induction of LRP by sodium-butyrate and the experiments using the ribozyme against LRP in KB 3-1 cells did not show the relationship between cisplatin-cytotoxicity and LRP, 48 although the direct evidence that LRP could transport cisplatin outside nucleus, is not still clear. Although our study showed no relation between LRP gene expression and clinical response to cisplatin-based chemotherapy, further examination will be required to conclude any relationship between cisplatin-cytotoxicity and LRP in vitro or in clinic.…”

Section: Mrp1 Mrp2mentioning

confidence: 99%

Copper‐transporting P‐type adenosine triphosphatase (ATP7B) as a cisplatin based chemoresistance marker in ovarian carcinoma: Comparative analysis with expression of MDR1, MRP1, MRP2, LRP and BCRP

Nakayama

Kanzaki

Ogawa

et al. 2002

Intl Journal of Cancer

131

View full text Add to dashboard Cite

Intrinsic or acquired resistance to chemotherapy is the major obstacle to overcome in the treatment of patients with solid carcinoma. Cisplatin is one of the most effective chemotherapeutic agents for treating ovarian carcinoma. Recently, copper-transporting P-type adenosine triphosphatase (ATP7B) has been demonstrated as one of the genes responsible for cisplatin resistance in vitro. We hypothesized that the expression of ATP7B gene increases resistance to cisplatin in ovarian carcinoma and a priori knowledge of its expression is important for the choice of therapy. The aim of our study was to assess the role of ATP7B gene in ovarian carcinoma and compare its expression with those of multidrug resistance-related transporters such as MDR1, MRP1, MRP2, LRP and BCRP genes. The transporters' gene expression profiles from 82 patients treated with cisplatin-based chemotherapy after surgery were assessed by RT-PCR. We did not observe any significant correlation between ATP7B gene expression and those of MDR1, MRP1, MRP2, LRP or BCRP. The expression level of ATP7B gene was significantly increased (p < 0.05) in patients with moderately-/poorlydifferentiated ovarian carcinomas treated with cisplatinbased chemotherapy, thus ATP7B may serve as an independent prognostic factor in these patients. In contrast, the expression level of MDR1, MRP1, MRP2, LRP and BCRP genes were not prognostic indicators of disease. These findings suggest that ATP7B gene may be considered as a novel chemoresistance marker and that inhibitor(s) of ATP7B might be useful, in patients with ovarian carcinoma treated with cisplatin-based chemotherapy.

show abstract

“…Their considerable abundance and striking evolutionary conservation argue for their important role in cell survival (4). Several lines of evidence have suggested that vaults may play an important role in intracellular detoxification processes, and thus may function in the multidrug resistance (MDR) of cancer cells (5).…”

Section: Introductionmentioning

confidence: 99%

Expression of Noncoding Vault RNA in Human Malignant Cells and Its Importance in Mitoxantrone Resistance

Gopinath

Wadhwa

Kumar

2010

Molecular Cancer Research

View full text Add to dashboard Cite

Several noncoding RNAs do vital cellular functions, including gene regulation and cell differentiation. Previously, we reported that vault RNA (vRNA) has the ability to recognize chemotherapeutic compounds, such as mitoxantrone, based on biophysical and biochemical analyses. In the present study, we show that human glioblastoma-, leukemia-, and osteocarcinoma-derived cell lines overexpress vRNA and exhibit higher resistance toward mitoxantrone. Interestingly, when vRNA expression was suppressed by RNA interference in these cells, the resistance progressively decreased. In agreement with these findings, overexpression of vRNA-1 caused resistance to mitoxantrone. These results suggest a role of vRNA in mitoxantrone resistance in malignant cells and justify further studies on the importance and application of noncoding RNAs in cancer chemotherapeutics. Mol Cancer Res; 8(11); 1536-46. ©2010 AACR.

show abstract

Multidrug Resistance and the Lung Resistance-Related Protein in Human Colon Carcinoma SW-620 Cells

Abstract: LRP is involved in resistance to doxorubicin, vincristine, etoposide, paclitaxel, and gramicidin D and has an important role in the transport of doxorubicin from the nucleus to the cytoplasm.

Cited by 170 publications

References 19 publications

Overexpression of the human major vault protein in astrocytic brain tumor cells

Overexpression of the human major vault protein in astrocytic brain tumor cells

Copper‐transporting P‐type adenosine triphosphatase (ATP7B) as a cisplatin based chemoresistance marker in ovarian carcinoma: Comparative analysis with expression of MDR1, MRP1, MRP2, LRP and BCRP

Expression of Noncoding Vault RNA in Human Malignant Cells and Its Importance in Mitoxantrone Resistance

Contact Info

Product

Resources

About